



A company of novel  
biopharmaceutical  
practices



A company of novel biopharmaceutical practices  
with 29 years of successful experience



- A portfolio of original medicines and vaccines, biotechnology-based products, branded generics, and dietary supplements.
- In-house R&D centre with patents in Russia and abroad for molecules and technologies.
- Full-cycle pharmaceutical manufacturing in compliance with EAEU and EU GMP standards.
- One of the largest Russian exporters of original medicines and vaccines.
- A partner of leading global pharmaceutical companies.



The development strategy is focused on providing patients with in-demand vaccines and biotech drugs for the prevention and treatment of infections, orphan diseases and cancers.

Values:



Vision:

Leading pharmaceutical innovations

Mission:

Expanding access to cutting-edge therapies

# petrovax company history

## 1996–2001

- Establishment of the pharmaceutical company Petrovax.
- Authorization of original medicinal products: the immunomodulator **Polyoxidonium®** and the first adjuvanted influenza vaccine, **Grippol®**.
- Acquisition of the **first patents** for molecules and technologies in Russia and globally.



## 2001–2005

- Awarded the **State Prize of the Russian Federation** for the development of Polyoxidonium® and Grippol®.
- Launch of the **first manufacturing facility** for active pharmaceutical ingredients (APIs) and finished dosage forms (FDF).
- Market launch of the original enzyme-based drug **Longidaza®**.
- Beginning of a partnership with **Solvay Pharma (Abbott)** to establish a pharmaceutical complex for the development and production of immunobiological drugs in the Moscow Region.



## 2006–2010

- Opening of a high-tech full-cycle **pharmaceutical manufacturing complex** in the Moscow Region.
- Manufacturing of the influenza vaccine **Grippol® Plus** in syringes and its supply for implementation of the Russian National Immunization Schedule, including over 15 million doses of pandemic influenza vaccines.
- Assignment of INN — **Azoximer bromide** for Polyoxidonium® by WHO.
- Launch of the **second production line** (vials and ampoules).



World Health  
Organization



## 2011–2015

- Implementation of a localization project for the manufacturing of the pneumococcal conjugate vaccine **Prevenar® 13** in collaboration with Pfizer.
- EU GMP certificate obtained; start of **Polyoxidonium®** exports to the EU.
- Registration of the innovative cosmetic product **Imoferaza®**.
- Introduction of a new investment strategy as part of the **Interros Group**.




## 2016–2020

- Authorization of Russia's first quadrivalent influenza vaccine, **Grippol® Quadrivalent**.
- Production of advanced thrombolytics **Metalyse®** and **Actilyse®** in partnership with Boehringer Ingelheim.
- Market launch of the generic **Velson®**.
- Large-scale **clinical research** program exploring the use of **Polyoxidonium®** and **Longidaza®** for prevention and treatment of **COVID-19**.
- Launch of the **third production line** (APIs and finished dosage forms).



## 2021–2024

- Launch of the **fourth production line** for injectable dosage forms. Start of construction of a new **biotechnological complex**.
- Expansion of the **product portfolio**: **Uronext®**, **VitaFerr®**, **ARTNEO®**, **Demefecil**, **Omegika®**, **Sundevit®**, **VitaFer® Express**, **Reflamaid®**, **Venarel®**.
- Localization of the **orphan drug Fabagal®** — a joint project with ISU ABXIS (South Korea) and the N.F. Gamaleya Center.
- Launch of the original oncology drug **Areima® (camrelizumab)** in collaboration with China's largest pharmaceutical company.



## An in-house research facility for preclinical studies enable the full cycle of medical product development and implementation.

Petrovax holds patents for new molecules and pharmaceutical manufacturing technologies in Russia and internationally. The company's investment program drives advancements in R&D.

- Search for innovative molecules and conduct of preclinical studies.
- Investigation of the mechanisms of action in disease pathogenesis.
- Demonstration of drug safety and efficacy in preclinical studies.
- Development of quality control methods and manufacturing technologies.
- Conduct of preclinical studies in compliance with GCP standards.
- Implementation of innovative technologies and optimization of manufacturing processes.



## International clinical studies

- International multicentre clinical study on the efficacy and safety of the Convidecia® vaccine for COVID-19 prevention, conducted in collaboration with CanSino Biologics, involving 40,000 volunteers (2020).
- International multicentre phase 3 clinical study on the efficacy and safety of Polyoxidonium® as part of complex therapy for patients with COVID-19 (2020).

research &  
development







advanced  
manufacturing  
facilities





## Full-cycle biotech production in compliance with EAEU and EU GMP standards

Our manufacturing processes cover the complete production cycle — from API synthesis to the release of sterile and non-sterile medicines, including immunological and biopharmaceutical products in various dosage forms.

**160**  
million doses  
of drugs per year



### Production Lines:

- Line 1 — Manufacturing of pre-filled syringes
- Line 2 — Production of ampoule and vial dosage forms, including lyophilized drugs
- Line 3 — API synthesis and soft/solid dosage forms production
- Line 4 — Manufacturing of injectable dosage forms

The company has implemented and effectively operates a Pharmaceutical Quality System (PQS).



Quality control of pharmaceuticals and vaccines is ensured at all stages of production, starting from sampling of raw materials to testing of finished products. Only approved suppliers of raw and auxiliary materials are used. The Quality Control Department employs more than one hundred specialists.

The company's pharmacovigilance system operates in compliance with international standards and Russian regulatory requirements, to ensure drug safety.

# international partnerships

Abbott

2008

## **Pioneering biopharmaceutical collaboration in Russia**

Petrovax partnered with Abbott to establish a biotechnology project focused on producing immunobiological drugs. In 2008, a pharmaceutical complex was launched in the Moscow Region, marking the first-ever production in Russia of the influenza vaccine Grippol® Plus in single-use syringes without preservatives.

Pfizer

2014

## **First import substitution project for high-tech vaccines in Russia**

Together with Pfizer, Petrovax implemented full-cycle technology for the local production of the 13-valent conjugate pneumococcal vaccine Prevenar® 13. Since 2014, over 45 million doses have been supplied to the Russian market, contributing to a 56% reduction in pneumonia-related mortality among infants in their first year of life<sup>1</sup>.

ISU ABXIS  
and N.F. Gamaleya  
Center

2022

## **First localization of an orphan drug in Russia, including biosynthesis of the API**

Petrovax, in partnership with ISU ABXIS and the N.F. Gamaleya Center, successfully completed a technology transfer project for the full-cycle production of Fabagal® (agalsidase beta) for the treatment of Fabry disease. Since 2024, the drug has been fully produced in Russia, from biosynthesis of the API to the finished dosage form.

Adimmune

2022

## **Quadrivalent influenza vaccine production**

In partnership with Taiwanese biopharmaceutical company Adimmune, Petrovax manufactures the quadrivalent influenza vaccine Grippol® Quadrivalent, using antigens certified by EMA and supplied by Adimmune.

N.F. Gamaleya  
Center

2023

## **New opportunities in cancer treatment**

Petrovax, in collaboration with a Chinese partner and the N.F. Gamaleya Center, is implementing a full-cycle localization project in Russia for the innovative immuno-oncology drug Areyma® (camrelizumab). This medicinal product is indicated for the treatment of several types of cancer, including nasopharyngeal carcinoma and esophageal cancer.

Areyma® was approved in Russia in 2024, with commercial supply to the domestic market commencing in May 2025.

As part of their ongoing strategic partnership, Petrovax and the N.F. Gamaleya Center are planning collaborative research projects to explore combination therapies involving mRNA-based biopharmaceuticals and Areyma®.

<sup>1</sup> According to Rosstat: <https://rosstat.gov.ru/compendium/document/13269>.



# export

Petrovax has been successfully operating in international pharmaceutical markets for over 20 years:

- One of the largest Russian exporters of influenza vaccines and original pharmaceutical products<sup>1</sup>;
- Products are available in more than 10 countries;
- EU GMP-certified since 2012.

**10** countries  
of export

## Competitive advantages:

- Original and in-demand portfolio of innovative products;
- High-tech manufacturing facilities in compliance with international GMP standards;
- Strong R&D investments and experience in implementing international projects.

Increasing export potential and expanding global reach are among the company's strategic goals.

<sup>1</sup> Pharmaceutical Bulletin, 2020 (<https://pharmvestnik.ru/articles/Strana-nepriznannyh-vakcin.html>).



# product portfolio



# Polyoxidonium®

INN: azoximer bromide

POLYEFFECT® AGAINST COLDS

An original Russian medicine with a complex mechanism of action for use in various therapeutic areas

In 2008 the WHO assigned an INN to azoximer bromide<sup>1</sup>.

## Rx & OTC

5 SKU

Rx & OTC


more than  
**2.5 mln packages**  
sold annually




for adults and children from 3 years




for adults and children from 6 months



for adults and children from 6 months



for children over 1 year



for adults

mucolytic  
immunomodulatory  
detoxifying  
anti-inflammatory

} **polyeffect®**

over  
**29**  
years  
of use

in 10 countries,  
including  
the European Union

**>150 clinical  
use studies**

involving more than  
21,750 patients  
aged 6 months to 90 years

### Indications

For the treatment and prevention of inflammatory and infectious diseases (viral, bacterial, and fungal) in acute and remission stages in adults and children.

#### Therapeutic areas:

- infectious diseases (pediatrics, therapy, ENT)
- immunology
- phthisiology
- oncology
- rheumatology

- surgery
- gynecology
- urology
- allergic diseases
- pulmonology



<https://polyoxidonium.ru>

<sup>1</sup> WHO Drug Information, Volume 22, № 1, 2008.

Rx & OTC

## Longidaza®

INN: bovyhialuronidase azoximer

### FREEDOM FROM FIBROSIS!

20  
years  
of use

An original enzyme-based drug (bovyhialuronidase azoximer — a conjugate of bovyhialuronidase and azoximer bromide) with a unique mechanism of action. Longidaza® is designed to reduce inflammation, break down fibrosis and adhesions, and combat bacterial biofilms as part of combination therapy for various conditions.<sup>1</sup>



#### Therapeutic areas:

- gynecology
- urology
- rheumatology
- surgery
- dermatology
- cosmetology
- pulmonology
- phthisiology

### #1 prescribed by gynecologists

for treating conditions associated  
with fibrosis and inflammation<sup>2</sup>

3 SKU  
(Rx & OTC)

over  
1.5 mln packages  
sold annually

#### Two clinical studies successfully completed in 2024:

NEW!

- Long-CoV-III-21: a randomized, double-blind, placebo-controlled study in adult patients with post-COVID-19 pulmonary complications.
- ADAM: a multicenter, randomized, prospective open-label study in patients with benign prostatic hyperplasia (BPH).



<https://longidaza.ru>



<sup>1</sup> WHO Drug Information, Volume 29, No. 3, 2015.

<sup>2</sup> Acc. to Prindex data, 2024

# Grippol® Plus

TRIVALENT inactivated subunit  
adjuvanted influenza vaccine


vaccines

Indications: prevention of influenza in children from 6 months old, adolescents, and adults of all ages — including pregnant women, the elderly, patients with chronic CNS, cardiovascular and bronchopulmonary diseases, autoimmune and allergic diseases, and immunocompromised patients



Trusted Worldwide  
**over 170 million doses**  
administered in Russia and internationally


**16**  
years  
of use



# Grippol® Quadrivalent

QUADRIVALENT inactivated subunit  
adjuvanted influenza vaccine

Indications: prevention of influenza in children from 6 months old, adolescents, and adults up to 60 years old.



Grippol® Quadrivalent  
Key Features:

- Antigen composition is updated annually in accordance with WHO recommendations.
- Contains the adjuvant **azoximer bromide (500 µg)**, which enhances both humoral and cellular immune responses.<sup>1, 2, 3</sup>
- Preservative-free and antibiotic-free formulation.
- Available in single-dose syringes with atraumatic needles, as well as in ampoules, and vials.



<https://grippol.ru>

<sup>1</sup> Low-dose influenza vaccine Grippol Quadrivalent with adjuvant Polyoxidonium induces a T helper-2 mediated humoral immune response and increases NK cell activity Talayev et al, Vaccine Volume 38, Issue 42, 29 September 2020, Pages 6485–6486

<sup>2</sup> Front. Immunol., Cytokine Profile in human Peripheral Blood Mononuclear Leukocytes Exposed to Immunoadjuvant and Adjuvant-Free Vaccines Against Influenza, M. Kostinov, 30 June 2020

<sup>3</sup> Komplier R., Neels P., Beyer W. et al. Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine. F1000Research 2022, 11: 25.)



## Prevenar® 13

Pneumococcal polysaccharide  
conjugate adsorbed thirteen-valent vaccine

### Indications:

A vaccine for the prevention of pneumococcal infections caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, including invasive infections (such as sepsis, bacteraemia, meningitis, and severe pneumonia) and non-invasive infections (such as community-acquired pneumonia and otitis media).

Recommended from 6 weeks of age onwards, with no age restriction.

Produced by Petrovax under a full-cycle production of finished dosage form in cooperation with Pfizer.

## Biotech products



## Forsedeno®

INN: denosumab

BioTech product for the treatment of osteoporosis that helps strengthen bones and reduce the risk of fractures, thereby improving patients' quality of life

### Indications:

Treatment of osteoporosis in postmenopausal women and in men who are at increased risk of fractures. It is also used to prevent bone loss in men with prostate cancer undergoing surgery or hormone therapy. Additionally, the drug is effective in treating bone loss associated with long-term glucocorticosteroid therapy in adult patients at increased risk of fractures.

# biotech products

## Areima®

INN: camrelizumab

**An original oncology medicine to treat oesophageal and nasopharyngeal cancers**

A monoclonal antibody that blocks the PD-1 receptor, reactivating tumor-specific cytotoxic T lymphocytes and stimulating antitumour immunity for the treatment of malignant neoplasms.

Areima® is indicated for the treatment of:

Recurrent or metastatic nasopharyngeal cancer in combination with cisplatin and gemcitabine as a first-line treatment.

Locally advanced, recurrent, or metastatic oesophageal squamous cell carcinoma:

- in combination with paclitaxel and cisplatin as first-line therapy;
- monotherapy following progression after chemotherapy.

The project for a full localized production in Russia is implemented in partnership with a Chinese company and the N.F. Gamaleya Center.



<https://camrelizumab.ru/>

## Fabagal®

INN: agalsidase beta

**A medicine for the treatment of rare (orphan) disease — Fabry disease**

Fabagal is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (a rare genetic disorder that leads to kidney damage, neuropathic pain in the limbs, congestive heart failure, myocardial infarction, and stroke).

The drug has been authorized and used in South Korea since 2014.

Localization in Russia, carried out in partnership with the N.F. Gamaleya Center and ISU Abxis, has ensured access to this vital therapy for Russian patients.



<https://fabagal.ru>

 Petrovax



## Reflamaid®

INN: fosfomycin

### AN AFFORDABLE TREATMENT FOR CYSTITIS

A first-choice antibiotic for the treatment of acute cystitis

#### Indications:

Acute episodes of recurrent bacterial cystitis; bacterial nonspecific urethritis; asymptomatic massive bacteriuria in pregnant women; postoperative urinary tract infections; prevention of infections during urinary tract surgeries; prevention of infections during transurethral diagnostic procedures.



The drug is typically administered as a single dose for uncomplicated cases.

Reflamaid® is suitable for all patients aged 12 and older, when prescribed by a doctor. It has a pleasant citrus flavor.

## Velson®

INN: melatonin

### SAY GOODBYE TO SLEEP PROBLEMS


A modern medicine for sleep and circadian rhythms' normalization

It helps to fall asleep in just 20 minutes, promotes deep sleep throughout the night, and ensures an easy wake-up in the morning. Velson® has a positive impact on memory, brain function, work performance, and emotions, while also helping to reduce stress reactions. It does not cause dependence (therapy termination after 6 months does not lead to rebound or withdrawal symptoms).



<https://velson24.ru>





## Demefecil

INN: dimetindene + phenylephrine

Gently relieves nasal congestion in children from 1 year of age

This combined vasoconstrictor and antihistamine helps to reduce nasal swelling and improve breathing. It is used to treat acute, vasomotor, chronic, and allergic rhinitis, as well as acute and chronic sinusitis, and acute otitis media (as an adjunctive treatment).

## Imoferaza®

THE ART OF SKINCARE

Specialized cream for the care of scarred and damaged skin

An innovative cosmetic cream based on immobilized hyaluronidase enzyme, specially formulated for the treatment of scar tissue of various origins.

It helps smoothen the skin surface and improve skin tone after acne, burns, injuries, plastic surgery, cosmetic procedures, or tattoo removal.



cosmetic products



<https://imoferaza.ru>

# food supplement



<https://omegika.ru>

## Omegika®

### THE NEW GENERATION OF OMEGA-3

A unique blend of crystal-clear Omega-3 concentrate and vitamin K2 to support beauty and youth

This ultra-purified Omega-3 concentrate is of the highest quality, containing EPA and DHA in the optimal proportions recommended by the WHO and GOED. The formula is enhanced with vitamin K2, which helps maintain the patency and elasticity of blood vessels. Omegika® is available in transparent capsules with a pleasant lemon fragrance and taste.

## Sundevit®

### THE POWER OF THE SUN IN ONE CAPSULE

A carefully selected dose of vitamin D3 combined with vitamin K2

The optimal dose<sup>1</sup> of vitamin D (2000 IU), enhanced with vitamin K2, helps strengthen immunity and supports the health of muscles, bones, and joints.




## Uronext®

### TRIPLE PROTECTION FOR THE URINARY TRACT

Complex remedy for urinary tract protection

Uronext® contains a unique combination of three natural ingredients: D-mannose, vitamin D3, and a special cranberry extract.

This European-quality product has a favourable safety profile and is suitable for use by diabetic patients, as well as pregnant and breastfeeding women<sup>2</sup>.



<https://uronext.ru>

<sup>1</sup> To maintain normal 25(OH)D > ng/mL levels in adults without obesity (BMI <30/m<sup>2</sup>) Vitamin D deficiency. REA draft clinical guidelines, 2021.

<sup>2</sup> When recommended and monitored by a physician





## ARTNEO®

FEEL GOOD IN MOTION WITH ARTNEO®!

### A new complex for joint and spine protection

An innovative formula featuring native type II collagen with a radically new mechanism of action. Carefully selected ingredients — undenatured type II collagen, MSM, boswellic acids, and vitamins C and D3 — work in synergy to help reduce discomfort, swelling, pain, and stiffness, while promoting the recovery and maintenance of joint and spinal function.



<https://artneo-collagen.ru>

## VitaFerr®

### YOUR IRON SUPPORT

#### Vitamin-enhanced iron chelate with a low risk of side effects

Gently supports normal iron levels, keeping you energized and in a good mood. VitaFerr® contains chelated iron (iron bisglycinate), enhanced with vitamins, which is easily absorbed and minimises side effects. Suitable for pregnant women.

The formula also includes essential nutrients to improve iron absorption and support healthy blood formation: vitamins C, B6, B12, and L-methylfolate (the bioactive form of folic acid).



<https://vitaferr.ru>



## VitaFerr® Express

### A tasty and convenient new-generation liposomal iron

VitaFerr® Express contains Fe(3+) iron pyrophosphate in a liposomal form, ensuring high bioavailability and excellent tolerance. It easily crosses the hepcidin barrier, ensuring optimal absorption.

Available in a convenient powder form with a delicious orange flavour. No water needed for consumption, and it leaves no unpleasant metallic aftertaste.

# food supplement

## Venarel® Inosit

### HARMONY FOR WOMEN'S HEALTH

A carefully selected combination of ingredients designed to support the healthy function of the female reproductive system. The optimal ratio 40:1 of myo-inositol and D-chiro-inositol, combined with a 200 µg dose of chromium, helps restore the menstrual cycle and address metabolic syndrome associated with polycystic ovary syndrome.



## Venarel® Prenatal 1

Vitamin and mineral complex for women during the preconception phase and the first trimester (1–12 weeks) of pregnancy. The ingredients are carefully selected based on current pregnancy management guidelines.<sup>1, 2, 3</sup>

<sup>1</sup> Clinical guidelines of the Ministry of Health of the Russian Federation Normal Pregnancy, 2023, Russian Society of Obstetricians and Gynecologists

<sup>2</sup> World Health Organization. (2017). Nutritional anaemias: tools for effective prevention and control. World Health Organization. 2017 <https://apps.who.int/iris/handle/10665/259425>. License: CC BY-NC-SA 3.0 IGO

<sup>3</sup> MP 2.3.1.0253-21. 2.3.1. Nutrition hygiene. Rational nutrition. Standards of physiological needs for energy and nutrients for various population groups of the Russian Federation. Methodological guidelines (approved by Chief State Sanitary Physician of the Russian Federation on 22.07.2021).


## Venarel® Prenatal 2

Vitamin and mineral complex for women in the second and third trimesters (13–40 weeks) of pregnancy and during breastfeeding. The ingredients are selected in accordance with current pregnancy management recommendations<sup>1, 2, 3</sup>.

<sup>1</sup> Clinical guidelines of the Ministry of Health of the Russian Federation Normal Pregnancy, 2023, Russian Society of Obstetricians and Gynecologists

<sup>2</sup> World Health Organization. (2017). Nutritional anaemias: tools for effective prevention and control. World Health Organization. 2017 <https://apps.who.int/iris/handle/10665/259425>. License: CC BY-NC-SA 3.0 IGO

<sup>3</sup> MP 2.3.1.0253-21. 2.3.1. Nutrition hygiene. Rational nutrition. Standards of physiological needs for energy and nutrients for various population groups of the Russian Federation. Methodological guidelines (approved by Chief State Sanitary Physician of the Russian Federation on 22.07.2021).





## **NPO Petrovax Pharm, LLC**

### Moscow Head Office

12 Presnenskaya emb.,  
Federation East Tower  
(Moscow City), fl. 38,  
Moscow 123112  
Russia

+7 495 730-74-45  
+7 945 730-75-60  
info@petrovax.ru

### Production facilities and warehouse

1 Sosnovaya street,  
Pokrov village, Podolsk,  
Moscow region 142 143  
Russia

+7 495 926-21-07  
npo@petrovax.ru

**[www.petrovax.com](http://www.petrovax.com)**

